Blood Pressure News and Research

RSS

Blood Pressure is the force of circulating blood on the walls of the arteries. Blood pressure is taken using two measurements: systolic (measured when the heart beats, when blood pressure is at its highest) and diastolic (measured between heart beats, when blood pressure is at its lowest). Blood pressure is written with the systolic blood pressure first, followed by the diastolic blood pressure (for example 120/80).

People with periodontal disease are at high risk for diabetes, survey finds

The study, led by Dr. Shiela Strauss, Associate Professor of Nursing and Co-Director of the Statistics and Data Management Core for NYU's Colleges of Dentistry and Nursing, examined data from 2,923 adult participants in the 2003-2004 National Health and Nutrition Examination Survey who had not been diagnosed with diabetes.

15 Dec 2009

Phase III clinical trial evaluating darusentan misses its co-primary efficacy endpoints

Gilead Sciences, Inc. today announced that DAR-312 (DORADO-AC), a Phase III clinical trial evaluating darusentan, the company’s endothelin receptor antagonist (ERA) for the treatment of resistant hypertension, did not achieve its co-primary efficacy endpoints of change from baseline to week 14 in trough sitting systolic blood pressure (SBP) and diastolic blood pressure (DBP) compared to placebo.

15 Dec 2009

Demystifying Psychiatry: A resource for patients and families

Psychiatric disorders are underdiagnosed, poorly treated and highly stigmatized, according to psychiatrists Charles F. Zorumski, M.D., and Eugene H. Rubin, M.D., Ph.D. So these Washington University physicians have written a book to address those problems.

15 Dec 2009

Champagne improves blood flow and reduces risk of cardiovascular diseases

Research from the University of Reading suggests that two glasses of Champagne a day may be good for your heart and circulation. The researchers have found that drinking Champagne wine daily in moderate amounts causes improvements in the way blood vessels function.

15 Dec 2009

Teva Pharmaceutical Industries receives approval for newly revised prescribing information for AZILECT

Teva Pharmaceutical Industries, Ltd. today announced the U.S. Food and Drug Administration (FDA) approved the newly revised prescribing information for AZILECT® (rasagiline tablets) reducing medication and food restrictions.

15 Dec 2009

Postmenopausal women who take antidepressants face increased risk for stroke and death

Postmenopausal women who take antidepressants face a small but statistically significant increased risk for stroke and death compared with those who do not take the drugs. The new findings are from the federally-funded, multi-institution, Women's Health Initiative Study sponsored by the National Institutes of Health, and the results are published in the December 14 online edition of Archives of Internal Medicine.

14 Dec 2009

ZYPREXA RELPREVV approved by FDA

The U.S. Food and Drug Administration (FDA) approved ZYPREXA RELPREVV (olanzapine) For Extended Release Injectable Suspension for the treatment of schizophrenia in adults, Eli Lilly and Company announced today.

14 Dec 2009

Premature newborn boys have poorer prognosis compared to newborn girls, says study

Among premature births - children born before the 37th week of pregnancy - newborn boys have a poorer prognosis than newborn girls. In her dissertation at Lund University in Sweden, the physician Emma Elsmén Steen has explored why male gender constitutes a risk factor for greater morbidity in these infants.

14 Dec 2009

Genentech announces Phase III study of Avastin in women treated with chemotherapy for advanced breast cancer

Genentech, Inc., a wholly owned member of the Roche Group, today announced results from a Phase III study (RIBBON 2) of Avastin® (bevacizumab) in women who had previously been treated with initial (first-line) chemotherapy for advanced HER2-negative breast cancer and needed additional (second-line) treatment.

14 Dec 2009

Results from Phase 2 trial evaluating Nexavar with capecitabine and paclitaxel presented

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced results from two collaborative group-sponsored randomized, double-blind, placebo-controlled Phase 2 trials were presented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS).

14 Dec 2009

Heart attacks peak during winter months, finds research

Research has found that heart attacks peak during the winter months, and the prevailing hypothesis has been that cold temperatures stress the heart. But in 2004, researchers analyzed 12 years of Los Angeles County death certificates and found that heart attack deaths also rise in the balmy Los Angeles winters.

14 Dec 2009

VNA of Greater Philadelphia expands its home health and specialty services in Bucks County

The Visiting Nurse Association (VNA) of Greater Philadelphia is expanding its traditional home health and specialty services to patients who reside in lower Bucks County.

14 Dec 2009

Special issue focuses on cardiovascular disease prevention and outcomes

Emerging research on cardiovascular risk factors and treatment effects are helping clinicians gain a better understanding of which patients are most likely to benefit from close monitoring, lifestyle changes and/or additional therapeutic interventions.

14 Dec 2009

Obese patients loosing moderate amount of weight improve their cardiovascular health, says study

Obese patients who lost a moderate amount of weight by eating less and exercising more improved their cardiovascular health, says a study at Washington University School of Medicine in St. Louis.

14 Dec 2009

Fulvestrant 500 mg reduces risk of disease progression in women with metastatic breast cancer

AstraZeneca (NYSE: AZN) today announced that data from a Phase III study of postmenopausal women with hormone receptor-positive advanced breast cancer presented at the San Antonio Breast Cancer Symposium (Abstract 25) showed treatment with fulvestrant (FASLODEX) 500 mg reduced the risk of disease progression (assessed as time to progression (TTP)) by 20%

11 Dec 2009

Schizophrenia: Once-monthly INVEGA SUSTENNA not inferior to bi-weekly RISPERDAL CONSTA

Treatment with once-monthly INVEGA® SUSTENNA(TM) is not inferior to treatment with bi-weekly RISPERDAL® CONSTA®, according to new data from a comparative study of both treatments in patients with schizophrenia. Results of the 13-week clinical trial were released this week.

10 Dec 2009

Second pivotal Phase 3 trial to evaluate investigational Lp-PLA2 inhibitor darapladib initiated

Attached is a press release issued earlier this morning by GlaxoSmithKline, announcing that GSK has initiated its second pivotal Phase 3 trial to evaluate the efficacy of long-term treatment with the investigational Lp-PLA2 inhibitor darapladib in men and women with acute coronary syndrome (ACS).

10 Dec 2009

New research shows increase risk of cardiovascular disease for people on low-carbohydrate high-fat diets

New scientific research has shown that low-carbohydrate high-fat diets, made popular by the likes of the Atkins diet, do not achieve more weight loss than low-fat high-carbohydrate diets. Worryingly, the research, lead by Dr Steven Hunter from the Royal Victoria Hospital, Belfast, also shows significantly increased risks of cardiovascular disease for people following low-carbohydrate high-fat diets

9 Dec 2009

Watson Pharmaceuticals' RAPAFLO demonstrates safety and tolerability in BPH treatment

Watson Pharmaceuticals, Inc. today announced that the results of an open-label extension of two Phase 3 studies, published in the December issue of the peer-reviewed journal Urology, demonstrate long-term safety and tolerability of RAPAFLO® (silodosin) for up to 52 weeks of treatment. RAPAFLO® is an effective and uniquely selective alpha blocker for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH), the number one reason patients visit urologists.

9 Dec 2009

March of Dimes poll finds majority of pregnant women worry about birth defects

The March of Dimes polled about 1,200 moms to find out exactly what it is that caused them to lose sleep (other than the fact they were pregnant!) while they were pregnant. The results were presented today at the March of Dimes National Communications Advisory Council luncheon where experienced, practicing obstetricians and gynecologists discussed the survey results, as well as some of the frequently asked questions their patients ask.

9 Dec 2009

Blood Pressure News and Research

Further Reading

People with periodontal disease are at high risk for diabetes, survey finds

Phase III clinical trial evaluating darusentan misses its co-primary efficacy endpoints

Demystifying Psychiatry: A resource for patients and families

Champagne improves blood flow and reduces risk of cardiovascular diseases

Teva Pharmaceutical Industries receives approval for newly revised prescribing information for AZILECT

Postmenopausal women who take antidepressants face increased risk for stroke and death

ZYPREXA RELPREVV approved by FDA

Premature newborn boys have poorer prognosis compared to newborn girls, says study

Genentech announces Phase III study of Avastin in women treated with chemotherapy for advanced breast cancer

Results from Phase 2 trial evaluating Nexavar with capecitabine and paclitaxel presented

Heart attacks peak during winter months, finds research

VNA of Greater Philadelphia expands its home health and specialty services in Bucks County

Special issue focuses on cardiovascular disease prevention and outcomes

Obese patients loosing moderate amount of weight improve their cardiovascular health, says study

Fulvestrant 500 mg reduces risk of disease progression in women with metastatic breast cancer

Schizophrenia: Once-monthly INVEGA SUSTENNA not inferior to bi-weekly RISPERDAL CONSTA

Second pivotal Phase 3 trial to evaluate investigational Lp-PLA2 inhibitor darapladib initiated

New research shows increase risk of cardiovascular disease for people on low-carbohydrate high-fat diets

Watson Pharmaceuticals' RAPAFLO demonstrates safety and tolerability in BPH treatment

March of Dimes poll finds majority of pregnant women worry about birth defects

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News